The Hong Kong Stock Exchange and Clearing Limited (HKEX) will launch Hang Seng Biotechnology Index futures on 28 November 2025, expanding its range of derivatives products in one of Hong Kong’s fastest-growing market sectors.
The new futures contract, which is subject to regulatory approval, will be based on the Hang Seng Biotechnology Index, which tracks the 30 largest Southbound biotech, pharmaceutical and medical device companies listed in Hong Kong.
Gregory Yu, Head of Markets at the Hong Kong Stock Exchange, said: “Thanks to innovation and strong global demand for healthcare, the biotechnology industry is one of the most exciting areas in capital markets today.
He added that the new Hang Seng Biotech Index Futures contracts will expand investors’ access to the sector’s potential and provide a “powerful hedging tool.”
The product will further support Hong Kong’s role as a leading derivatives and risk management hub in Asia, providing investors with a way to manage exposure to one of the region’s most dynamic sectors, the Hong Kong Stock Exchange said.
Since the 2018 Hong Kong Stock Exchange listing reforms, biotech and healthcare listings have soared. There are now more than 260 companies listed in the sector, with a combined market capitalization exceeding HK$4.8 trillion, up 400% since 2018.
The Hong Kong Stock Exchange said margin rates and additional details will be announced before the product launch.